| Title |
Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand
|
|---|---|
| Published in |
PharmacoEconomics, May 2014
|
| DOI | 10.1007/s40273-014-0154-x |
| Pubmed ID | |
| Authors |
Rachel Webber-Foster, Giorgi Kvizhinadze, Gareth Rivalland, Tony Blakely |
| Abstract |
There have been recent important changes to adjuvant regimens and costs of taxanes for the treatment of early breast cancer, requiring a re-evaluation of comparative cost effectiveness. In particular, weekly paclitaxel is now commonly used but has not been subjected to cost-effectiveness analysis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 18% |
| Student > Ph. D. Student | 7 | 14% |
| Other | 4 | 8% |
| Student > Bachelor | 3 | 6% |
| Student > Postgraduate | 3 | 6% |
| Other | 11 | 22% |
| Unknown | 13 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 14% |
| Psychology | 4 | 8% |
| Decision Sciences | 2 | 4% |
| Economics, Econometrics and Finance | 2 | 4% |
| Other | 7 | 14% |
| Unknown | 16 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2018.
All research outputs
#7,200,244
of 22,756,196 outputs
Outputs from PharmacoEconomics
#813
of 1,816 outputs
Outputs of similar age
#70,236
of 226,407 outputs
Outputs of similar age from PharmacoEconomics
#14
of 33 outputs
Altmetric has tracked 22,756,196 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 1,816 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,407 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.